Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
ADVITOS
company
About
ADVITOS developed the CE-marked and globally patented ADVOS technology.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- €20M
- Founded date
- Jan 1, 2005
- Number Of Employee
- 51 - 100
- Operating Status
- Active
ADVOS is the world’s first method for the combined multi-organ support of liver, lung, kidney, and acid-base balance. Based on the principle of albumin dialysis, ADVOS allows extracorporeal fluid-based elimination of CO2, hepatic toxins, water-soluble and protein-bound nephrotoxins, as well as the correction of metabolic and respiratory acidosis. The ADVOS method works with typical dialysis accesses and flow rates and does not require any gas exchangers for CO2 elimination.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
€20M
ADVITOS has raised a total of
€20M
in funding over 2 rounds. Their latest funding was raised on
Jun 10, 2021 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 10, 2021 | Series Unknown | €20M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
ADVITOS is funded by 1 investors.
European Innovation Council
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
European Innovation Council
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
